Target Name: RBM34
NCBI ID: G23029
Review Report on RBM34 Target / Biomarker Content of Review Report on RBM34 Target / Biomarker
RBM34
Other Name(s): KIAA0117 | RNA-binding motif protein 34 | RNA-binding protein 34 | RBM34 variant 1 | RBM34_HUMAN | RNA binding motif protein 34 | epididymis secretory sperm binding protein | RNA-binding protein 34 (isoform 1) | RNA binding motif protein 34, transcript variant 1

RBM34: A Potential Drug Target Or Biomarker

RBM34 is a protein that is expressed in almost all human tissue cells, including neurons, muscle cells, and endothelial cells. Its name comes from its molecular weight of 34 kDa. In recent years, more and more studies have shown that RBM34 plays an important role in a variety of diseases, such as neurodegenerative diseases, tumors, and metabolic disorders. These studies indicate that RBM34 may be a potential drug target or biomarker, and therefore has received widespread attention. This article will introduce the structure, function, biological activity and current research progress of RBM34.

structure

RBM34 is a 440-amino-acid protein with a highly conserved amino acid sequence. Its N-terminus contains a phenylalanine residue, its C-terminus contains a serine residue, and it contains some amino acids such as cysteine, alanine, and glutamic acid in the middle region. The expression pattern of RBM34 in cells is independent of cell type, so it can be studied in various types of cells.

Function

RBM34 plays an important role in a variety of physiological and pathological processes. It is involved in neuronal proliferation, differentiation, and synapse formation in neurons. In muscle cells, RBM34 is involved in muscle cell contraction and relaxation processes. In endothelial cells, RBM34 is involved in the regulation of endothelial cell proliferation, migration, and permeability.

RBM34 is also associated with a variety of diseases, such as neurodegenerative diseases, tumors, and metabolic disorders. For example, studies have shown that overexpression of RBM34 is associated with the progression of Parkinson's disease and neuronal damage. In addition, RBM34 is also related to tumor occurrence and progression, so it is considered a potential tumor biomarker.

biological activity

Currently, there are various studies exploring the biological activity of RBM34. Some studies have shown that RBM34 can be used as a therapeutic target for neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease and multiple sclerosis. For example, some studies have shown that the use of RBM34 inhibitors can slow neuronal damage and improve neuronal function, thereby improving symptoms in patients with neurodegenerative diseases.

In addition, some studies have shown that RBM34 can be used as a biomarker for tumors and metabolic disorders. For example, some studies have shown that the expression level of RBM34 can be used to evaluate the prognosis of tumor patients and is related to the survival rate of tumor patients. In addition, some studies have shown that RBM34 can be used to treat metabolic disorders such as obesity and diabetes.

current research

Currently, there are a variety of studies exploring the biological activity of RBM34, including neurodegenerative diseases, tumors, and metabolic disorders. Some studies are also exploring the drug development prospects of RBM34.

in conclusion

RBM34 is a protein expressed in a variety of tissue cells and has a variety of biological functions. More and more studies have shown that RBM34 plays an important role in the fields of neurodegenerative diseases, tumors and metabolic disorders. These studies indicate that RBM34 may be a potential drug target or biomarker, and therefore has received widespread attention. Future studies will continue to explore the biological functions and drug development prospects of RBM34.

Protein Name: RNA Binding Motif Protein 34

The "RBM34 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBM34 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1 | RCAN2 | RCAN3 | RCAN3AS | RCBTB1 | RCBTB2 | RCC1 | RCC1L | RCC2 | RCCD1 | RCE1 | RCHY1 | RCL1 | RCN1 | RCN1P2 | RCN2 | RCN3 | RCOR1 | RCOR2 | RCOR3 | RCSD1 | RCVRN | RD3 | RD3L | RDH10 | RDH11 | RDH12 | RDH13 | RDH14 | RDH16 | RDH5 | RDH8 | RDM1 | RDUR | RDX | RDXP2 | Reactive oxygen species (ROS) | REC114 | REC8 | RECK | RECQL | RECQL4 | RECQL5 | REELD1 | REEP1 | REEP2